摘要
11例中晚期肿瘤患者(包括原发性肝癌7例,淋巴瘤、胃癌、肺癌、转移性肝癌各1例),采用简化IL-2/LAK细胞疗法治疗。其中1例淋巴瘤病灶完全消失。1例HCC病灶有所缩小,4例HCC病灶稳定。2例转移淋巴结缩小或消失,3例血性胸腹水转移为黄色,多数患者自我症状改善,9例仍生存。除个别病例发生尿少,水肿等毛细血管渗漏综合征外,余未见特殊副作用。
The adoptive immunotherapy with lymphokine-activated killer (LAK) cells and mterlcukin-2 (IL-2) were carried out and evaluated in 11 resident patients with advanced cancer LAK cells were produced by stimulating the lymphocytes collected from allogcncic spleen or blood, or autologous blood with IL-2 (2×210~3units/ml) in vitro for 5 to 10 days and were administrated in the patients along with IL-2. The treatments were composed of 4 to 6 times of intermittent infusion of LAK cells and IL-2 (2×10~5 to 4×10~4). The results of the treatment, as monitored by B-ultrasonography, CT scan and physical examination are categorized into the following: complete response in 1 patient with non-Hodgkin's lymphoma, partial response in 2 (1 with metastatic liver cancer, 1 with lung cancer), minor response in 5 (4 with HCC, 1 with gastric carcinoma), no change in 4 with HCC and prograssive disease in 2 with HCC. The side effects included transient fever (9 patients) and capilliary leakage symdrome (1 patient).
出处
《南通医学院学报》
1993年第4期344-347,353,共4页
ACTA Academiae Medicinae Nantong
关键词
白细胞介素2
癌
免疫方法
LAK cells, Interleukin-2, Adoptive Immunotherapy
